雅培突破性可吸收支架Esprit获FDA批准，用于膝下慢性肢体缺血-动脉橙

雅培突破性可吸收支架Esprit获FDA批准，用于膝下慢性肢体缺血

2024-04-29 BioSpace 等6家媒体报道 FDA动态





FDA批准了雅培的Esprit BTK系统，这是一种新型可溶性支架，用于治疗膝下慢性肢体缺血。这标志着外周动脉疾病（PAD）治疗取得了重大进展，因为以前的选择有限，目前的标准是球囊血管成形术，结果往往不佳。Esprit BTK系统由类似于溶解缝线的材料制成，可保持动脉开放，并在完全溶解之前输送药物依维莫司以帮助血管愈合，为PAD患者取得更好的预后提供了希望。（摘要由动脉网AI生成）

关联公司

 Abbott

2024-04-29 Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

BioSpace
2024-04-29 Abbott Dissolving Stent Granted Earlier-Than-Expected FDA Approval

mddionline
2024-04-29 Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

CISION
2024-04-29 Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod

RTTNews
2024-04-29 Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries Below the Knee

雅培
2024-04-30 Abbott Earns FDA Approval For Dissolving Stent That Unclogs Arteries Below The Knee

MedCity News